Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study (Q33371000)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

multicenter clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

D A Richards

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K A Boehm

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D M Waterhouse

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D J Wagener

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S S Krishnamurthi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Rosemurgy

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W Grove

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Macdonald

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Gulyas

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Clark

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K D Dasse

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

26 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1096-1102

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Chronic oral administration of CI-994: a phase 1 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL081

21 January 2018

Identifiers

10.1093/ANNONC/MDL081

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33371000&oldid=1536572082"